Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence

Cancer

Volumn 119, Issue 7, 2013, Pages 1349-1356

  Ho, Allen S ^a   Tsao, Gabriel J ^a   Chen, Frank W ^a   Shen, Tianjie ^a   Kaplan, Michael J ^a   Colevas, A Dimitrios ^a   Fischbein, Nancy J ^a   Quon, Andrew ^a   Le, Quynh Thu ^a   Pinto, Harlan A ^a   Fee, Willard E ^a   Sunwoo, John B ^a   Sirjani, Davud ^a   Hara, Wendy ^a   Yao, Mike ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

computed tomography; head and neck cancer; integrated positron emission tomography and computed tomography; positron emission tomography; salvage therapy; surveillance

Indexed keywords

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CHEMORADIOTHERAPY; COHORT ANALYSIS; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; DISEASE SURVEILLANCE; FALSE POSITIVE RESULT; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY;

EID: 84875360561     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27892     Document Type: Article

References (38)

1. Goodwin WJ Jr,. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope. 2000; 110 (3 pt 2 suppl 93): 1-18.
2. Wong LY, Wei WI, Lam LK, Yuen AP,. Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck. 2003; 25: 953-959.
3. Adams S, Baum RP, Stuckensen T, Bitter K, Hor G,. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med. 1998; 25: 1255-1260.
4. Schoder H, Yeung HW,. Positron emission imaging of head and neck cancer, including thyroid carcinoma. Semin Nucl Med. 2004; 34: 180-197.
5. Corry J, Rischin D, Hicks RJ, Peters LJ,. The role of PET-CT in the management of patients with advanced cancer of the head and neck. Curr Oncol Rep. 2008; 10: 149-155.
6. Schoder H, Yeung HW, Gonen M, Kraus D, Larson SM,. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology. 2004; 231: 65-72.
7. Gupta T, Master Z, Kannan S, et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011; 38: 2083-2095.
8. Ryan WR, Fee WE Jr, Le QT, Pinto HA,. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope. 2005; 115: 645-650.
9. Porceddu SV, Pryor DI, Burmeister E, et al. Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck. 2011; 33: 1675-1682.
10. Hillner BE, Tosteson AN, Song Y, et al. Growth in the use of PET for six cancer types after coverage by Medicare: additive or replacement? J Am Coll Radiol. 2012; 9: 33-41.
11. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB,. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer. 1994; 73: 187-190.
12. Beswick DM, Gooding WE, Johnson JT, Branstetter BF IV,. Temporal patterns of head and neck squamous cell carcinoma recurrence with positron-emission tomography/computed tomography monitoring. Laryngoscope. 2012; 122: 1512-1517.
13. Abgral R, Querellou S, Potard G, et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med. 2009; 50: 24-29.
14. Lee JC, Kim JS, Lee JH, et al. F-18 FDG-PET as a routine surveillance tool for the detection of recurrent head and neck squamous cell carcinoma. Oral Oncol. 2007; 43: 686-692.
15. Krabbe CA, Pruim J, Dijkstra PU, et al. 18F-FDG PET as a routine posttreatment surveillance tool in oral and oropharyngeal squamous cell carcinoma: a prospective study. J Nucl Med. 2009; 50: 1940-1947.
16. Greven KM, Williams DW III, McGuirt WF Sr, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck. 2001; 23: 942-946.
17. Lowe HJ, Ferris TA, Hernandez PM, Weber SC,. STRIDE-an integrated standards-based translational research informatics platform. AMIA Annu Symp Proc. 2009; 2009: 391-395.
18. Edge SB, American Cancer Society, American College of Surgeons, et al. AJCC cancer staging handbook from the AJCC cancer staging manual. 7th ed. New York, NY: Springer; 2010.
19. Ong SC, Schoder H, Lee NY, et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer. J Nucl Med. 2008; 49: 532-540.
20. Liao CT, Chang JT, Wang HM, et al. Salvage therapy in relapsed squamous cell carcinoma of the oral cavity: how and when? Cancer. 2008; 112: 94-103.
21. Zafereo ME, Hanasono MM, Rosenthal DI, et al. The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. Cancer. 2009; 115: 5723-5733.
22. Yao M, Graham MM, Smith RB, et al. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report. Int J Radiat Oncol Biol Phys. 2004; 60: 1410-1418.
23. Greven KM, Williams DW III, Keyes JW Jr, et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer. 1994; 74: 1355-1359.
24. Connell CA, Corry J, Milner AD, et al. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck. 2007; 29: 986-995.
25. Brouwer J, de Bree R, Hoekstra OS, et al. Screening for distant metastases in patients with head and neck cancer: is chest computed tomography sufficient? Laryngoscope. 2005; 115: 1813-1817.
26. de Bree R, Deurloo EE, Snow GB, Leemans CR,. Screening for distant metastases in patients with head and neck cancer. Laryngoscope. 2000; 110 (3 pt 1): 397-401.
27. Loh KS, Brown DH, Baker JT, Gilbert RW, Gullane PJ, Irish JC,. A rational approach to pulmonary screening in newly diagnosed head and neck cancer. Head Neck. 2005; 27: 990-994.
28. Uyl-de Groot CA, Senft A, de Bree R, Leemans CR, Hoekstra OS,. Chest CT and whole-body 18F-FDG PET are cost-effective in screening for distant metastases in head and neck cancer patients. J Nucl Med. 2010; 51: 176-182.
29. Chen F, Sonobe M, Sato K, et al. Pulmonary resection for metastatic head and neck cancer. World J Surg. 2008; 32: 1657-1662.
30. Winter H, Meimarakis G, Hoffmann G, et al. Does surgical resection of pulmonary metastases of head and neck cancer improve survival? Ann Surg Oncol. 2008; 15: 2915-2926.
31. Shiono S, Kawamura M, Sato T, et al. Pulmonary metastasectomy for pulmonary metastases of head and neck squamous cell carcinomas. Ann Thorac Surg. 2009; 88: 856-860.
32. Wedman J, Balm AJ, Hart AA, et al. Value of resection of pulmonary metastases in head and neck cancer patients. Head Neck. 1996; 18: 311-316.
33. Liu D, Labow DM, Dang N, et al. Pulmonary metastasectomy for head and neck cancers. Ann Surg Oncol. 1999; 6: 572-578.
34. Spector ME, Chinn SB, Rosko AJ, et al. Diagnostic modalities for distant metastasis in head and neck squamous cell carcinoma: are we changing life expectancy? Laryngoscope. 2012; 122: 1507-1511.
35. Chen AY, Vilaseca I, Hudgins PA, Schuster D, Halkar R,. PET-CT vs contrast-enhanced CT: what is the role for each after chemoradiation for advanced oropharyngeal cancer? Head Neck. 2006; 28: 487-495.
36. Zundel MT, Michel MA, Schultz CJ, et al. Comparison of physical examination and fluorodeoxyglucose positron emission tomography/computed tomography 4-6 months after radiotherapy to assess residual head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011; 81: e825-e832.
37. Moeller BJ, Rana V, Cannon BA, et al. Prospective risk-adjusted [18F]fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol. 2009; 27: 2509-2515.
38. Zhang I, Branstetter BF IV, Beswick DM, Maxwell JH, Gooding WE, Ferris RL,. The benefit of early PET/CT surveillance in HPV-associated head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2011; 137: 1106-1111.